OPTNA
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
Opthea Limited
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Opthea Limited - Ordinary Fully Paid Ex Option Deferred
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Performance graph isn't available yet for this share
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in OPTNA
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in OPTNA
N/A
OPTNA investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in OPTNA also invest in...
Want more shares? Try these...
Openpay Group Ltd. is a payments technology company that offers a buy now, pay later product. The company is headquartered in Melbourne, Victoria. The company went IPO on 2019-12-16. The firm delivers an omnichannel financing solution that offers buy now pay later (BNPL) payment solutions in the form of next generation BNPL 2.0 product. Its BNPL 2.0 provides the gateway to complete transactions with payback terms of up to 24-months, across underserved BNPL verticals, including automotive, healthcare, home improvement, memberships, education, and retail. The Company’s B2B (business to business) offers OpyPro, a Software as a service (SaaS) based platform that allows companies to manage trade accounts end-to-end, including applications, credit checks, approvals and account management in the one system. The firm provides services to customers and merchants in Australia, New Zealand, the United Kingdom and United States.
📊 Share price
$0.20 AUD
Opthea Ltd. is a clinical stage biopharmaceutical company that engages in the development of biological therapeutics for the treatment of progressive retinal diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in the development and commercialization of therapies primarily for eye disease. The Company’s lead asset, OPT-302, is a novel biologic inhibitor of VEGF-C and VEGF-D, for use in combination with VEGF-A inhibitors for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The Company’s principal activities include the progression of the Company’s Phase III registration trials of OPT-302 for wet AMD. The company also manufactures OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. The Company’s development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).
📊 Share price